Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.
The user is discussing hair regrowth after 7 months of using topical minoxidil and RU58841, with some microneedling. They are hesitant to switch to finasteride or dutasteride and are seeking input on whether there is new growth or just more miniaturization.
A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.
A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.
A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.
The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.
User reports 6-month progress using Fin, Min, Nizoral, and Dermaroll for hair loss. Others comment on visible improvement and suggest waiting up to 2 years for full effects.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
The conversation discusses skepticism about "5 in 1" and "3 in 1" hair loss treatments, which combine Dutasteride or Finasteride with Minoxidil, being overpriced and potentially ineffective. Users suggest buying individual components separately for cost savings and question the effectiveness of low concentrations in these combined products.
Ninan50 uses 0.6 minoxidil, 0.05 finasteride, biotin, and dermarolling for hair loss. Plans to increase to 0.7 minoxidil and 0.125 finasteride, with positive progress seen.
The user has been using finasteride for 6 months and recently added topical minoxidil and finasteride. They are seeking advice on whether to expect full recovery and are considering long-term maintenance with these treatments.
A hair transplant experience after 6 months, with 4100 grafts, which took 3 months to stop looking obvious and included finasteride treatment. It also discusses the differences between DHI and FUE methods.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.
The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.
A user developed a rash after 3 years of using Kirkland minoxidil foam, possibly due to a change in ingredients. They are considering switching to Foligain or Rogaine foam to avoid further issues.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
Six months after a 4000 graft hair transplant, the individual has seen little to no results. They are currently using finasteride, minoxidil, ketoconazole, and biotin but not microneedling. The advice given is to wait another 2-6 months as full results can take up to a year, and to consider the possibility of shock loss.
PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.
Oral minoxidil may require potassium for effectiveness, and diuretics taken for water retention might affect this process. The user plans to start taking potassium to address potential issues with minoxidil's effectiveness.
The conversation discusses a hair loss treatment regimen involving high doses of dutasteride, finasteride, and minoxidil, with concerns about safety and potential side effects. Users advise against the excessive use of these medications, suggesting more moderate approaches and consulting a doctor.
User shared progress pictures showing significant hair improvement after 6 months of Minoxidil and 3 months of Finasteride, along with dermastamping twice a week. Another user encouraged them to continue the good work.
The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.
The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.